Stacy Loeb1. 1. Department of Urology, Population Health, and the Laura & Isaac Perlmutter Cancer Center, New York University and the Manhattan Veterans Affairs Medical Center, NY, USA.
Abstract
INTRODUCTION: Many new markers are now available as an aid for decisions about prostate biopsy for men without prostate cancer, and/or to improve risk stratification for men with newly diagnosed prostate cancer. METHODS: A literature review was performed on currently available markers for use in decisions about prostate biopsy and initial prostate cancer treatment. RESULTS: Although total prostate-specific antigen cutoffs were traditionally used for biopsy decisions, PSA elevations are not specific. Repeating the PSA test, and adjusting for factors like age, prostate volume and changes over time can increase specificity for biopsy decisions. The Prostate Health Index (phi) and 4K Score are new PSA-based markers that can be offered as second-line tests to decide on initial or repeat prostate biopsy. The PCA3 urine test and ConfirmMDx tissue test are additional options for repeat biopsy decisions. For men with newly diagnosed prostate cancer, genomic tests are available to refine risk classification and may influence treatment decisions. CONCLUSIONS: Numerous secondary testing options are now available that can be offered to patients deciding whether to undergo prostate biopsy and those with newly diagnosed prostate cancer.
INTRODUCTION: Many new markers are now available as an aid for decisions about prostate biopsy for men without prostate cancer, and/or to improve risk stratification for men with newly diagnosed prostate cancer. METHODS: A literature review was performed on currently available markers for use in decisions about prostate biopsy and initial prostate cancer treatment. RESULTS: Although total prostate-specific antigen cutoffs were traditionally used for biopsy decisions, PSA elevations are not specific. Repeating the PSA test, and adjusting for factors like age, prostate volume and changes over time can increase specificity for biopsy decisions. The Prostate Health Index (phi) and 4K Score are new PSA-based markers that can be offered as second-line tests to decide on initial or repeat prostate biopsy. The PCA3 urine test and ConfirmMDx tissue test are additional options for repeat biopsy decisions. For men with newly diagnosed prostate cancer, genomic tests are available to refine risk classification and may influence treatment decisions. CONCLUSIONS: Numerous secondary testing options are now available that can be offered to patients deciding whether to undergo prostate biopsy and those with newly diagnosed prostate cancer.
Authors: Monique J Roobol; Heidi A van Vugt; Stacy Loeb; Xiaoye Zhu; Meelan Bul; Chris H Bangma; Arno G L J H van Leenders; Ewout W Steyerberg; Fritz H Schröder Journal: Eur Urol Date: 2011-11-15 Impact factor: 20.096
Authors: Matthew R Cooperberg; David J Pasta; Eric P Elkin; Mark S Litwin; David M Latini; Janeen Du Chane; Peter R Carroll Journal: J Urol Date: 2005-06 Impact factor: 7.450
Authors: Peter J Boström; Anders S Bjartell; James W F Catto; Scott E Eggener; Hans Lilja; Stacy Loeb; Jack Schalken; Thorsten Schlomm; Matthew R Cooperberg Journal: Eur Urol Date: 2015-04-23 Impact factor: 20.096
Authors: Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman Journal: N Engl J Med Date: 2004-05-27 Impact factor: 91.245
Authors: Claire de la Calle; Dattatraya Patil; John T Wei; Douglas S Scherr; Lori Sokoll; Daniel W Chan; Javed Siddiqui; Juan Miguel Mosquera; Mark A Rubin; Martin G Sanda Journal: J Urol Date: 2015-01-28 Impact factor: 7.450
Authors: J Cuzick; D M Berney; G Fisher; D Mesher; H Møller; J E Reid; M Perry; J Park; A Younus; A Gutin; C S Foster; P Scardino; J S Lanchbury; S Stone Journal: Br J Cancer Date: 2012-02-23 Impact factor: 7.640
Authors: Andrew J Vickers; Angel M Cronin; Gunnar Aus; Carl-Gustav Pihl; Charlotte Becker; Kim Pettersson; Peter T Scardino; Jonas Hugosson; Hans Lilja Journal: BMC Med Date: 2008-07-08 Impact factor: 8.775
Authors: Sofia Lage-Vickers; Juan Bizzotto; Maria Pia Valacco; Pablo Sanchis; Sergio Nemirovsky; Estefania Labanca; Carlos Scorticati; Osvaldo Mazza; Antonina Mitrofanova; Nora Navone; Elba Vazquez; Javier Cotignola; Geraldine Gueron Journal: Commun Biol Date: 2021-01-22